Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1.
Pyrimidinediones, a novel class of compounds, have previously been shown to possess antiviral activity at nanomolar concentrations. One member of this class of compounds, IQP-0528, was selected as the lead molecule for formulation development owing to its stability at physiologically relevant conditions, wide therapeutic window, and antiviral activity in the nanomolar range. Here, we report the development of two vaginal gels--3.0% hydroxyethyl cellulose (HEC) formulation and a 0.65% Carbopol formulation--for the sustained delivery of IQP-0528. Stability studies under accelerated conditions confirmed the chemical stability of IQP-0528 and mechanical stability of the gel formulation for 3 months. In vitro release studies revealed that diffusion-controlled release of IQP-0528 occurred over 6 h, with an initial lag time of approximately 1 h. Based on the drug release profile, the 3.0% HEC gel was selected as the lead formulation for safety and activity evaluations. The in vitro and ex vivo safety evaluations showed no significant loss in cell viability or significant inflammatory response after treatment with a 3.0% HEC gel containing 0.25% IQP-0528. In an in vitro HIV-1 entry inhibition assay, the lead formulation showed an 50% effective concentration of 0.14 μg/ml for gel in culture media, which corresponds to ∼0.001 μM IQP-0528. The antiviral activity was further confirmed by using polarized cervical explants, in which the formulation showed complete protection against HIV infection. In summary, these results are encouraging and warrant further evaluation of IQP-0528 gel formulations in in vivo models, as well as the development of alternative formulations for the delivery of IQP-0528 as a microbicide.
Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, 20 S 2030 E, Salt Lake City, Utah 84112, USA.
Alamelu
A
Mahalingam
Adam P
AP
Simmons
Shweta R
SR
Ugaonkar
Karen M
KM
Watson
Charlene S
CS
Dezzutti
Lisa C
LC
Rohan
Robert W
RW
Buckheit
Patrick F
PF
Kiser
D000818:Animals; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology*; D005260:Female; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D011744:Pyrimidinones / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology*; D013552:Swine; D014621:Vagina / Q000378:metabolism; D014622:Vaginal Creams, Foams, and Jellies / Q000008:administration & dosage* / Q000737:chemistry
D019380:Anti-HIV Agents; D011744:Pyrimidinones; D014622:Vaginal Creams, Foams, and Jellies
J Pharm Sci. 2010 Mar;99(3):1265-77
19739112
Int J Pharm. 2006 Aug 2;318(1-2):1-14
16621366
Crit Rev Ther Drug Carrier Syst. 2000;17(5):509-55
11108158
Drug Dev Ind Pharm. 2000 Sep;26(9):913-24
10914315
Sex Transm Dis. 2002 Oct;29(10):597-605
12370527
Biol Reprod. 2004 Sep;71(3):761-9
15128598
PLoS One. 2010 Feb 19;5(2):e9310
20174579
Int J Pharm. 2005 Nov 23;305(1-2):105-11
16226413
SADJ. 2006 Jun;61(5):200-3
16892714
Antimicrob Agents Chemother. 2007 May;51(5):1770-9
17353237
BMC Infect Dis. 2006 Jun 01;6:90
16740164
Antimicrob Agents Chemother. 2008 Jan;52(1):225-36
17967909
Antivir Chem Chemother. 2007;18(5):259-75
18046959
Toxicol In Vitro. 2006 Aug;20(5):689-98
16309879
Adv Drug Deliv Rev. 2005 Nov 3;57(11):1713-23
16183163
Retrovirology. 2004 Jul 06;1:16
15238164
Contraception. 2000 Dec;62(6):321-6
11239620
Antimicrob Agents Chemother. 2001 Feb;45(2):393-400
11158731
Drugs R D. 2004;5(5):245-57
15357624
Am J Public Health. 1990 Apr;80(4):460-2
2316768
Biol Reprod. 1999 Feb;60(2):508-14
9916021
J Pharm Sci. 1962 Aug;51:802-4
13907274
Antimicrob Agents Chemother. 2004 Oct;48(10):3834-44
15388443
AIDS Res Hum Retroviruses. 2005 Oct;21(10):845-53
16225411
Pharm Sci Technol Today. 2000 Oct 1;3(10):359-364
11050460
J Int Assoc Physicians AIDS Care (Chic). 2003 Jul-Sep;2(3):102-5
14556428
Annu Rev Med. 2008;59:455-71
17892435
Pharm Res. 2010 Nov;27(11):2478-91
20842411
Pharm Res. 1999 Sep;16(9):1325-30
10496646
J Pharm Sci. 2008 Jan;97(1):9-21
17721937
J Pharm Sci. 2008 Oct;97(10):4228-39
18338805
Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9835-40
18606986
Antivir Chem Chemother. 2007;18(3):141-51
17626598
Antivir Chem Chemother. 2009;19(4):143-50
19374141
Science. 2008 Jul 25;321(5888):532-4
18653884
Adv Drug Deliv Rev. 2005 Nov 3;57(11):1692-712
16182407
Int J Pharm. 2005 Nov 23;305(1-2):2-12
16246513
Science. 2010 Sep 3;329(5996):1168-74
20643915